Compound Id,Name,DTT sensitivity (if > 30 % loss of activity at 20 µM),Inhibition [%] Primary Screen (single point; 20 µM),"HC
Inhibition [%] (triplicate, 20 µM)","HC
 AV Inhibition [%] (triplicate, 20 µM)
slope","AV inhibition +DTT 15min 
duplicates",IC50 µM 15 min,IC50 µM slope,%inhibition_d03-KU_LW,%Inh in caco2 cells,MOA,Target,Phase,SubCategory,Chemically reactive,MotherPlate,Well Motherplate,Row Dest.Plate,Column Dest.Plate,Group,"AV Inhibiton
 Slope","AV Inhibiton
 15min","%Inhibition
_slope PS","%Inhibition
_15min PS","VeroE6% 
Confluence_d03","VeroE6 % 
Inhibition_d03",Chemically reactive?,Molecule_ID,Standardized_Molecule_InChIKey,Standardized_Molecule_Smiles,Is_active
SPE_K72327355,baicalein,sensitiv,97.8,95.96,82.52,-20.06,0.02,0.88,5.07,-5.61,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",Preclinical,Enzyme,N,,,,,,,,,,,,,12166,FXNFHKRTJBSTCS-UHFFFAOYSA-N,Oc1cc2OC(=CC(=O)c2c(O)c1O)c3ccccc3,1
SPE_K29359156,EBSELEN,sensitiv,99.99,100.38,99.67,-16.34,0.03,0.05,-2.87,4.96,"cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor",ALB,Phase 2/Phase 3,Enzyme,Y,,,,,,,,,,,,,104,DYEFUKCXAQOFHX-UHFFFAOYSA-N,O=C1N([Se]c2ccccc12)c3ccccc3,1
SPE_K32730239,SU3327,sensitiv,99.9,100.26,99.65,25.93,0.03,0.0,-33.06,3.52,JNK inhibitor,MAPK8,Preclinical,Kinase,possibly,,,,,,,,,,,,,11274,NQQBNZBOOHHVQP-UHFFFAOYSA-N,Nc1nnc(Sc2ncc(s2)[N+](=O)[O-])s1,1
SPE_K29254801,THIRAM,sensitiv,99.88,99.92,99.62,12.72,0.05,0.08,-14.73,22.44,,JAK2,Launched,Other,Y,,,,,,,,,,,,,11206,KUAZQDVKQLNFPE-UHFFFAOYSA-N,CN(C)C(=S)SSC(=S)N(C)C,1
SPE_A56592690,PX-12,sensitiv,100.06,99.84,99.71,7.75,0.14,0.46,-0.69,6.95,thioredoxin inhibitor,"TXN, TXNRD1",Phase 2,Enzyme,Y,,,,,,,,,,,,,5185,BPBPYQWMFCTCNG-UHFFFAOYSA-N,CCC(C)SSc1ncc[nH]1,1
SPE_A61194565,BENSERAZIDE HYDROCHLORIDE,sensitiv,99.45,99.49,97.95,-8.69,0.14,0.38,-31.28,-1.43,DOPA decarboxylase inhibitor,DDC,Launched,Enzyme,N,,,,,,,,,,,,,9599,BNQDCRGUHNALGH-UHFFFAOYSA-N,NC(CO)C(=O)NNCc1ccc(O)c(O)c1O,1
SPE_K81330143,Tideglusib,sensitiv,90.94,99.3,99.28,-4.89,0.15,0.14,-3.46,-2.12,glycogen synthase kinase inhibitor,GSK3B,Phase 2,Kinase,Y,,,,,,,,,,,,,3878,PMJIHLSCWIDGMD-UHFFFAOYSA-N,O=C1SN(C(=O)N1Cc2ccccc2)c3cccc4ccccc34,1
SPE_K34149328,bonaphthone,sensitiv,95.47,99.37,100.31,37.44,0.16,0.38,-1.01,-4.75,,other,Phase 3,Other,Y,,,,,,,,,,,,,4448,MXWZRRPNVLCHMY-UHFFFAOYSA-N,Brc1ccc2C(=O)C(=O)C=Cc2c1,1
SPE_K01614093,Dihydromyricetin,sensitiv,99.7,99.67,99.36,-14.3,0.18,0.3,1.12,-1.32,,other,Preclinical,Other,N,,,,,,,,,,,,,1209,KJXSIXMJHKAJOD-LSDHHAIUSA-N,O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c3cc(O)c(O)c(O)c3,1
SPE_K80970344,pyrrolidine-dithiocarbamate,sensitiv,100.75,99.48,99.67,-11.26,0.21,0.86,0.33,-4.76,NFkB pathway inhibitor,"HSD11B1, RELA",Preclinical,Enzyme,Y,,,,,,,,,,,,,12367,VSWDORGPIHIGNW-UHFFFAOYSA-N,SC(=S)N1CCCC1,1
SPE_K32744045,DISULFIRAM,sensitiv,99.73,99.92,99.49,36.15,0.22,0.55,-21.56,0.44,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",Launched,DNA-RNA-Viral,Y,,,,,,,,,,,,,8240,AUZONCFQVSMFAP-UHFFFAOYSA-N,CCN(CC)C(=S)SSC(=S)N(CC)CC,1
SPE_K78342372,Hematoxylin (Hydroxybrazilin),sensitiv,99.59,100.92,99.32,24.72,0.22,0.17,-7.28,-7.34,,other,Preclinical,Other,N,,,,,,,,,,,,,12313,WZUVPPKBWHMQCE-XJKSGUPXSA-N,Oc1cc2C[C@@]3(O)COc4c(O)c(O)ccc4[C@H]3c2cc1O,1
SPE_K08893438,CCG 50014,sensitiv,100.54,100.28,99.5,2.39,0.23,0.43,-4.05,-0.64,G protein signaling inhibitor,"RGS4, RGS8",Preclinical,Enzyme,N,,,,,,,,,,,,,10732,QUIIIYITNGOFEI-UHFFFAOYSA-N,Cc1ccc(cc1)N2SC(=O)N(Cc3ccc(F)cc3)C2=O,1
SPE_K21771665,MERBROMIN,MERBROMIN,100.92,100.02,100.3,96.68,0.24,0.76,-49.28,15.99,antiseptic,other,Launched,Enzyme,Y,,,,,,,,,,,,,11027,OHCFGBLQZMYRTR-UHFFFAOYSA-M,O[Hg]c1c(O)c(Br)cc2C(=C3C=C(Br)C(=O)C=C3Oc12)c4ccccc4C(=O)O,1
SPE_K26530649,carboxypyridine-disulfide,sensitiv,100.32,98.87,99.73,1.52,0.24,0.32,4.33,-4.06,,other,Phase 2,Other,Y,,,,,,,,,,,,,11142,GSASOFRDSIKDSN-UHFFFAOYSA-N,OC(=O)c1ccc(SSc2ccc(cn2)C(=O)O)nc1,1
SPE_K33308633,INCA-6,sensitiv,99.24,100.42,100.09,-14.27,0.24,0.44,3.2,23.75,calcineurin inhibitor,NFATC1,Preclinical,Enzyme,Y,,,,,,,,,,,,,11287,GCHPUOHXXCNSQL-UHFFFAOYSA-N,O=C1C=CC(=O)C2=C1C3c4ccccc4C2c5ccccc35,1
SPE_K39706510,MIRA-1,sensitiv,100.11,100.05,99.64,-9.02,0.29,0.82,-3.57,-3.0,apoptosis stimulant,other,Preclinical,Enzyme,Y,,,,,,,,,,,,,11438,YXEWPGYLMHXLPS-UHFFFAOYSA-N,CCC(=O)OCN1C(=O)C=CC1=O,1
SPE_K73982490,BI-78D3,sensitiv,96.41,101.15,99.6,21.23,0.3,0.9,-22.67,-6.41,JNK inhibitor,,,,possibly,,,,,,,,,,,,,12207,QFRLDZGQEZCCJZ-UHFFFAOYSA-N,[O-][N+](=O)c1cnc(SC2=NNC(=O)N2c3ccc4OCCOc4c3)s1,1
SPE_K48963429,riodoxol,sensitiv,99.73,98.93,99.44,-18.76,0.33,0.64,-1.52,9.24,other antibiotic,other,Launched,Antibacterial,possibly,,,,,,,,,,,,,8432,XKFZYVWWXHCHIX-UHFFFAOYSA-N,Oc1c(I)cc(I)c(O)c1I,1
SPE_K43149758,Myricetin (Cannabiscetin),sensitiv,100.32,100.07,97.23,-9.96,0.4,1.12,1.9,-2.92,"androgen receptor agonist, cytochrome P450 inhibitor",PIK3CG,Preclinical,NHR,N,,,,,,,,,,,,,11508,IKMDFBPHZNJCSN-UHFFFAOYSA-N,OC1=C(Oc2cc(O)cc(O)c2C1=O)c3cc(O)c(O)c(O)c3,1
SPE_K54395039,PR-619,PR-619,97.57,98.84,99.68,97.92,0.41,0.82,-34.29,3.19,DUB inhibitor,other,Preclinical,Enzyme,Y,,,,,,,,,,,,,11794,ZXOBLNBVNROVLC-UHFFFAOYSA-N,Nc1nc(N)c(SC#N)cc1SC#N,1
SPE_K33457401,BRONOPOL,sensitiv,99.89,100.48,99.44,-5.66,0.42,0.72,17.6,-9.83,,other,Launched,Other,Y,,,,,,,,,,,,,11292,LVDKZNITIUWNER-UHFFFAOYSA-N,OCC(Br)(CO)[N+](=O)[O-],1
SPE_K54098378,NT157,sensitiv,79.36,78.14,79.49,-4.64,0.48,0.94,2.86,5.11,IGF-1 inhibitor,IGF1R,Preclinical,Kinase,Y,,,,,,,,,,,,,11784,NIPUPOUEGOSAAO-OWOJBTEDSA-N,Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O,1
SPE_K38727704,IPA-3,sensitiv,91.25,98.46,98.95,-61.13,0.51,1.14,0.59,5.22,p21 activated kinase inhibitor,PAK1,Preclinical,Kinase,Y,,,,,,,,,,,,,11418,RFAXLXKIAKIUDT-UHFFFAOYSA-N,Oc1ccc2ccccc2c1SSc3c(O)ccc4ccccc34,1
SPE_K76022557,APOMORPHINE HYDROCHLORIDE,sensitiv,79.01,83.67,94.81,-23.03,0.52,0.72,0.22,0.61,dopamine receptor agonist,"DRD2, HTR5A",Launched,GPCR,N,,,,,,,,,,,,,617,VMWNQDUVQKEIOC-CYBMUJFWSA-N,CN1CCc2cccc3c2[C@H]1Cc4ccc(O)c(O)c34,1
SPE_K40624912,ZM-39923,sensitiv,75.66,78.16,86.76,6.02,0.58,1.57,-25.86,4.81,JAK inhibitor,"JAK1, JAK3",Preclinical,Kinase,N,,,,,,,,,,,,,11456,JSASWRWALCMOQP-UHFFFAOYSA-N,CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc3ccccc3,1
SPE_K68928792,Aldoxorubicin,sensitiv,100.9,100.66,99.64,-9.5,0.58,1.25,-7.53,1.62,topoisomerase inhibitor,TOP2A,Phase 3,DNA-RNA-Viral,Y,,,,,,,,,,,,,882,OBMJQRLIQQTJLR-USGQOSEYSA-N,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)\C(=N\NC(=O)CCCCCN6C(=O)C=CC6=O)\CO,1
SPE_K86972824,OLTIPRAZ,sensitiv,93.83,97.56,101.75,1.56,0.62,1.44,6.11,5.22,"nuclear factor erythroid derived, like (NRF2) activator",ANG,Phase 3,NHR,Y,,,,,,,,,,,,,8437,CKNAQFVBEHDJQV-UHFFFAOYSA-N,CC1=C(SSC1=S)c2cnccn2,1
SPE_K66898851,SANGUINARIUM CHLORIDE,sensitiv,-57.31,13.95,72.52,-23.1,0.64,1.21,-44.98,-7.51,apoptosis stimulant,CASP3,Phase 1,Enzyme,Y,,,,,,,,,,,,,332,GYQPLLUBTBEWII-UHFFFAOYSA-N,C[N]1=Cc2c3OCOc3ccc2c4ccc5cc6OCOc6cc5c14,1
SPE_A79857384,Captan,sensitiv,99.84,100.34,100.09,9.79,0.67,1.39,-25.08,8.18,,other,Phase 1,Other,Y,,,,,,,,,,,,,10433,LDVVMCZRFWMZSG-UHFFFAOYSA-N,ClC(Cl)(Cl)SN1C(=O)C2CC=CCC2C1=O,1
SPE_K55591206,(-)-Epigallocatechin Gallate,sensitiv,95.26,98.89,97.04,-22.36,0.72,1.29,-1.41,6.28,bacterial DNA gyrase inhibitor,"ELANE, EP300, FASN, KAT2B, MMP14, MMP2",Phase 2/Phase 3,Antibacterial,N,,,,,,,,,,,,,522,WMBWREPUVVBILR-WIYYLYMNSA-N,Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c4cc(O)c(O)c(O)c4,1
SPE_A39390670,Rabeprazole (sodium),sensitiv,94.26,94.2,96.66,-10.54,0.74,1.3,0.71,4.39,"ATPase inhibitor, gastrin inhibitor",ATP4A,Launched,Enzyme,N,,,,,,,,,,,,,7231,YREYEVIYCVEVJK-UHFFFAOYSA-N,COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,1
SPE_K64191834,"CBS, N-Cyclohexyl-2-benzothiazolesulfenamide",sensitiv,70.06,69.59,-12.11,-16.44,0.77,48.64,-5.75,43.36,,,,,Y,,,,,,,,,,,,,12010,DEQZTKGFXNUBJL-UHFFFAOYSA-N,C1CCC(CC1)NSc2nc3ccccc3s2,1
SPE_K15025317,BAY-11-7082,sensitiv,95.73,99.6,99.44,-12.5,0.82,1.56,-32.64,0.23,NFkB pathway inhibitor,RELA,Preclinical,Enzyme,Y,,,,,,,,,,,,,10883,DOEWDSDBFRHVAP-KRXBUXKQSA-N,Cc1ccc(cc1)S(=O)(=O)\C=C\C#N,1
SPE_K68408467,PROFLAVINE HEMISULFATE,sensitiv,60.89,76.55,99.87,20.41,0.83,2.02,19.09,95.79,topical anesthetic,F2,Phase 2,Protease,N,,,,,,,,,,,,,6835,WDVSHHCDHLJJJR-UHFFFAOYSA-N,Nc1ccc2cc3ccc(N)cc3nc2c1,1
SPE_K40331046,CR8-(R),sensitiv,99.45,99.9,97.64,1.59,0.84,2.35,-6.33,76.63,CDK inhibitor,CCNA2,Preclinical,Kinase,N,,,,,,,,,,,,,11450,HOCBJBNQIQQQGT-LJQANCHMSA-N,CC[C@H](CO)Nc1nc(NCc2ccc(cc2)c3ccccn3)c4ncn(C(C)C)c4n1,1
SPE_K48684885,BAY-11-7085,sensitiv,100.48,98.95,99.34,-7.9,0.84,2.74,-35.68,3.21,NFkB pathway inhibitor,NFKBIA,Preclinical,Enzyme,Y,,,,,,,,,,,,,11643,VHKZGNPOHPFPER-ONNFQVAWSA-N,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,1
SPE_K91509126,piceatannol,sensitiv,-78.95,9.91,51.45,-88.48,0.84,3.79,-0.4,-3.77,SYK inhibitor,"ATP5A1, ATP5B, ATP5C1, IRF3",Preclinical,Kinase,N,,,,,,,,,,,,,12581,CDRPUGZCRXZLFL-OWOJBTEDSA-N,Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1,1
SPE_M75036822,hemin,hemin,96.57,101.08,96.43,100.99,0.88,2.1,-4.79,62.89,enzyme inducer,other,Launched,Other,N,,,,,,,,,,,,,12766,FEDYMSUPMFCVOD-UHFFFAOYSA-N,CC1=C(C=C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)c(C=C)c5C)c(C)c4CCC(=O)O)c(CCC(=O)O)c3C,1
SPE_K36889451,Tetramethylthiuram monosulfide,sensitiv,99.93,99.85,99.67,-6.75,0.94,1.5,-11.69,19.33,,other,Preclinical,Other,Y,,,,,,,,,,,,,11378,REQPQFUJGGOFQL-UHFFFAOYSA-N,CN(C)C(=S)SC(=S)N(C)C,1
SPE_A42270467,TENATOPRAZOLE,sensitiv,69.12,90.15,97.05,-9.75,0.97,2.73,-5.45,-1.51,ATPase inhibitor,IDO1,Phase 2,Enzyme,N,,,,,,,,,,,,,9509,ZBFDAUIVDSSISP-UHFFFAOYSA-N,COc1ccc2[nH]c(nc2n1)S(=O)Cc3ncc(C)c(OC)c3C,1
SPE_K31471398,dihydrexidine,sensitiv,98.33,98.95,97.46,-15.06,1.05,1.37,16.67,-0.75,dopamine receptor agonist,"DRD1, DRD2, DRD3, DRD4, DRD5",Phase 2,GPCR,N,,,,,,,,,,,,,6930,BGOQGUHWXBGXJW-RHSMWYFYSA-N,Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O,1
SPE_A53134341,Ro-106-9920,sensitiv,99.95,98.77,97.74,19.87,1.12,5.36,-39.1,-2.43,NFkB pathway inhibitor,other,Preclinical,Enzyme,N,,,,,,,,,,,,,10255,JFSXSNSCPNFCDM-UHFFFAOYSA-N,O=S(c1ccccc1)c2ccc3nnnn3n2,1
SPE_K79555887,RI-1,sensitiv,99.17,100.11,99.75,15.24,1.14,1.63,-7.96,-14.63,,RAD51,Preclinical,Other,Y,,,,,,,,,,,,,12338,MWSUIZKGNWELRF-UHFFFAOYSA-N,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c3ccc(Cl)c(Cl)c3,1
SPE_K95676198,JAK3-inhibitor-V,sensitiv,94.54,92.27,90.56,-11.79,1.24,3.45,-2.14,7.11,JAK inhibitor,JAK3,Preclinical,Kinase,Y,,,,,,,,,,,,,12667,FOTCGZPFSUWZBN-UHFFFAOYSA-N,C=CC(=O)c1ccc2ccccc2c1,1
SPE_K26502378,VANITIOLIDE,sensitiv,99.97,99.41,98.38,-0.97,1.32,3.47,-1.02,0.86,,other,Preclinical,Other,Y,,,,,,,,,,,,,11140,WQYRHRAZNNRDIA-UHFFFAOYSA-N,COc1cc(ccc1O)C(=S)N2CCOCC2,1
SPE_K62790656,caracemide,sensitiv,96.39,94.71,45.83,17.48,1.33,5.68,-2.56,27.85,ribonucleotide reductase inhibitor,RRM1,Phase 2,Enzyme,Y,,,,,,,,,,,,,8431,JURAJLFHWXNPHG-UHFFFAOYSA-N,CNC(=O)ON(C(=O)C)C(=O)NC,1
SPE_K14274271,XL228,sensitiv,44.75,99.19,91.79,-9.58,1.49,4.39,-18.81,4.95,"Abl kinase inhibitor, insulin growth factor receptor inhibitor, src inhibitor","IGF1R, SRC",Phase 1,Kinase,N,,,,,,,,,,,,,3813,ALKJNCZNEOTEMP-UHFFFAOYSA-N,CC(C)c1cc(CNc2nc(Nc3cc([nH]n3)C4CC4)cc(n2)N5CCN(C)CC5)on1,1
SPE_A30370660,SENNOSIDE A,SENNOSIDE A,103.3,100.33,82.95,101.21,1.59,3.99,3.34,-10.64,glycoside agonist,other,Launched,Enzyme,N,,,,,,,,,,,,,10124,IPQVTOJGNYVQEO-FPJYKMGYSA-N,OC[C@H]1O[C@H](Oc2cccc3[C@H](C4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5C(=O)c7c(O)cc(cc47)C(=O)O)c8cc(cc(O)c8C(=O)c23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O,1
SPE_K88701661,dimercaptosuccinic-acid,sensitiv,98.94,98.43,97.95,-8.73,1.72,3.85,0.36,30.07,chelating agent,DNMT1,Launched,Other,Y,,,,,,,,,,,,,12523,ACTRVOBWPAIOHC-XIXRPRMCSA-N,OC(=O)[C@H](S)[C@H](S)C(=O)O,1
SPE_K55160477,Benzo[d]thiazole-2(3H)-thione,sensitiv,93.96,63.55,14.61,-5.69,1.74,3.66,-0.06,24.6,,,,,Y,,,,,,,,,,,,,11806,YXIWHUQXZSMYRE-UHFFFAOYSA-N,S=C1Nc2ccccc2S1,1
SPE_A91031770,SB-268262,SB-268262,96.73,100.33,99.89,73.76,1.87,3.62,-37.35,3.99,,,,,N,,,,,,,,,,,,,10491,YXHLPJQQPOMPGE-UHFFFAOYSA-N,CN(C(=O)c1ccc(c(c1)[N+](=O)[O-])S(=O)c2nccs2)c3ccccc3C,1
SPE_M87138257,Acriflavine hydrochloride,Acriflavine hydrochloride,59.0,67.97,99.1,68.22,1.93,5.1,-26.74,69.41,hypoxia inducible factor inhibitor,HIF1A,Launched,Enzyme,Y,,,,,,,,,,,,,6864,NLROCEWTIPMDKX-UHFFFAOYSA-N,C[N]1=C2C=C(N)C=CC2=Cc3ccc(N)cc13,1
SPE_K13629382,eseroline-(-),sensitiv,91.54,75.47,48.89,-0.64,1.99,4.22,-32.35,-3.78,acetylcholinesterase inhibitor,"OPRD1, OPRM1",Preclinical,Protease,N,,,,,,,,,,,,,10853,HKGWQUVGHPDEBZ-OLZOCXBDSA-N,CN1CC[C@]2(C)[C@H]1N(C)c3ccc(O)cc23,1
SPE_K49597925,SB-747651A,sensitiv,96.16,96.9,88.17,0.27,2.07,5.27,10.78,2.33,,,,,N,,,,,,,,,,,,,11674,MBCJUIJWPYUEBX-UHFFFAOYSA-N,CCn1c(nc2cncc(CNC3CCNCC3)c12)c4nonc4N,1
SPE_K53156781,omega-(4-Iodophenyl)pentadecanoic acid,sensitiv,95.0,98.38,96.65,4.0,2.25,4.86,1.34,3.32,,other,Preclinical,Other,N,,,,,,,,,,,,,11759,YAONEUNUMVOKNQ-UHFFFAOYSA-N,OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1,1
SPE_K73027814,oxyfedrine,sensitiv,90.8,90.54,84.5,-7.26,2.35,6.34,1.3,6.41,adrenergic receptor agonist,other,Launched,GPCR,N,,,,,,,,,,,,,3961,GDYUVHBMFVMBAF-LIRRHRJNSA-N,COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c2ccccc2,1
SPE_A09838294,Oridonin (Isodonol),sensitiv,98.2,95.09,83.91,1.82,2.57,5.18,-30.2,-4.1,BCL inhibitor,BCL2,Preclinical,,N,,,,,,,,,,,,,9983,VPZCKRKZFRCZMX-QRTGZHHDSA-N,CC1(C)CC[C@H](O)[C@]23CO[C@](O)(C[C@H]12)[C@@]45[C@H](O)[C@@H](CC[C@H]34)C(=C)C5=O,1
SPE_A87130939,Nordihydroguaiaretic acid,sensitiv,98.51,66.91,53.19,-13.95,2.59,2.68,-3.02,21.4,lipoxygenase inhibitor,ALOX5,Launched,Enzyme,N,,,,,,,,,,,,,10467,HCZKYJDFEPMADG-UHFFFAOYSA-N,CC(Cc1ccc(O)c(O)c1)C(C)Cc2ccc(O)c(O)c2,1
SPE_A88548664,SKF-38393,sensitiv,99.85,99.87,96.78,-11.34,2.63,2.92,14.07,0.27,dopamine receptor agonist,"CALY, DRD1, DRD5",Preclinical,GPCR,N,,,,,,,,,,,,,10475,JUDKOGFHZYMDMF-UHFFFAOYSA-N,Oc1cc2CCNCC(c3ccccc3)c2cc1O,1
SPE_K09426783,TAS-103 (dihydrochloride),sensitiv,96.13,97.46,90.69,42.19,2.99,4.68,-10.25,92.56,topoisomerase inhibitor,TOP1,Phase 1,DNA-RNA-Viral,N,,,,,,,,,,,,,5872,ROWSTIYZUWEOMM-UHFFFAOYSA-N,CN(C)CCNc1nc2cc(O)ccc2c3c4ccccc4C(=O)c13,1
SPE_K01493881,apigenin,sensitiv,94.54,97.48,94.09,-9.22,3.02,8.48,6.35,-2.89,"casein kinase inhibitor, cell proliferation inhibitor","AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1",Preclinical,Kinase,Y,,,,,,,,,,,,,10566,KZNIFHPLKGYRTM-UHFFFAOYSA-N,Oc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)cc3O2,1
SPE_A00842753,Oleuropein,sensitiv,93.79,99.58,97.1,-15.31,3.38,3.34,0.29,-0.51,estrogen receptor agonist,GPER1,Phase 2,NHR,N,,,,,,,,,,,,,9926,RFWGABANNQMHMZ-DXNYSGJVSA-N,COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)\C(=C/C)\C1CC(=O)OCCc3ccc(O)c(O)c3,1
SPE_K18898553,Salvianolic Acid B,sensitiv,90.8,88.03,89.76,-1.77,3.42,5.44,-5.08,4.81,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,Phase 2,Protease,Y,,,,,,,,,,,,,5133,SNKFFCBZYFGCQN-PDVBOLEISA-N,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c2ccc(O)c3O[C@H]([C@H](C(=O)O[C@H](Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5,1
SPE_A69512159,CARBIDOPA,sensitiv,90.73,94.48,91.29,-7.65,3.55,3.81,-2.21,4.56,,,,,N,,,,,,,,,,,,,8319,TZFNLOMSOLWIDK-UHFFFAOYSA-N,CC(Cc1ccc(O)c(O)c1)(NN)C(=O)O,1
SPE_K29834313,Myricitrin (Myricitrine),sensitiv,90.56,77.87,36.72,-10.29,3.66,5.41,-3.21,-11.41,PKC inhibitor,"NOS1, PRKCA",Preclinical,Kinase,N,,,,,,,,,,,,,11220,DCYOADKBABEMIQ-FLCVNNLFSA-N,C[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4cc(O)c(O)c(O)c4)[C@@H](O)[C@H](O)[C@H]1O,1
SPE_K20313525,rosmarinic-acid,sensitiv,95.67,94.92,94.14,-17.76,3.86,4.96,8.26,-7.31,GABA transaminase inhibitor,"MCL1, TYR",Launched,Enzyme,Y,,,,,,,,,,,,,8605,DOUMFZQKYFQNTF-WUTVXBCWSA-N,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c2ccc(O)c(O)c2,1
SPE_K34068325,Delavirdine (mesylate),Delavirdine (mesylate),81.96,86.67,87.01,67.54,3.99,9.94,2.87,-1.61,non-nucleoside reverse transcriptase inhibitor,CYP3A4,Launched,Enzyme,N,,,,,,,,,,,,,6323,WHBIGIKBNXZKFE-UHFFFAOYSA-N,CC(C)Nc1cccnc1N2CCN(CC2)C(=O)c3cc4cc(NS(=O)(=O)C)ccc4[nH]3,1
SPE_K90817094,Bedaquiline,sensitiv,99.45,95.66,93.96,-11.09,4.36,6.37,-5.76,6.62,ATPase inhibitor,other,Launched,Enzyme,N,,,,,,,,,,,,,4082,QUIJNHUBAXPXFS-XLJNKUFUSA-N,COc1nc2ccc(Br)cc2cc1[C@@H](c3ccccc3)[C@@](O)(CCN(C)C)c4cccc5ccccc45,1
SPE_K65716359,exifone,sensitiv,95.46,91.64,71.37,-13.46,4.38,11.26,3.68,-1.48,nootropic agent,TYR,Withdrawn,Enzyme,N,,,,,,,,,,,,,7272,XEDWWPGWIXPVRQ-UHFFFAOYSA-N,Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O,1
SPE_K36201510,Verbascoside,sensitiv,94.19,95.36,97.52,-16.78,4.54,5.3,-5.69,-2.07,"PKC inhibitor, NFkB pathway inhibitor",other,Phase 2/Phase 3,Kinase,N,,,,,,,,,,,,,349,FBSKJMQYURKNSU-ZLSOWSIRSA-N,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O,1
SPE_K49788188,heclin,sensitiv,57.09,64.65,-4.95,-30.47,4.95,10.28,-1.19,42.36,,,,,Y,,,,,,,,,,,,,11683,SPTWXRJNCFIDRQ-ZHACJKMWSA-N,CCc1oc(\C=C\C(=O)Nc2ccc(cc2)C(=O)C)cc1,1
SPE_K38860038,JK-184,sensitiv,76.0,81.19,83.32,-23.74,5.05,10.27,-2.17,65.21,hedgehog pathway inhibitor,other,Preclinical,Enzyme,N,,,,,,,,,,,,,11420,ROYXIPOUVGDTAO-UHFFFAOYSA-N,CCOc1ccc(Nc2nc(cs2)c3c(C)nc4ccccn34)cc1,1
SPE_K97360717,N-oxydiethylenebenzothiazole-2-sulfenamide,sensitiv,98.98,99.82,99.24,-2.93,5.05,8.43,1.94,64.61,,other,Preclinical,Other,Y,,,,,,,,,,,,,12705,MHKLKWCYGIBEQF-UHFFFAOYSA-N,C1CN(CCO1)Sc2nc3ccccc3s2,1
SPE_K82028950,CGH2466,sensitiv,46.84,76.32,57.37,-20.44,5.37,10.39,-0.89,2.62,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",Preclinical,GPCR,N,,,,,,,,,,,,,12403,BEPGKLOHQTXUHX-UHFFFAOYSA-N,Nc1nc(c2ccc(Cl)c(Cl)c2)c(s1)c3ccncc3,1
SPE_A58955223,sulforaphane,sulforaphane,89.0,77.59,-2.13,63.45,5.48,166.06,-2.71,94.22,"anticancer agent, aryl hydrocarbon receptor antagonist",NFE2L2,Phase 2,NHR,Y,,,,,,,,,,,,,841,SUVMJBTUFCVSAD-UHFFFAOYSA-N,CS(=O)CCCCN=C=S,1
SPE_K58146797,"5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one",sensitiv,98.2,68.88,19.92,7.35,5.65,14.31,11.89,-9.44,,,,,N,,,,,,,,,,,,,7018,PXINDYJACXPZIN-UHFFFAOYSA-N,CCN1C(=O)NN=C1c2ccc(Cl)cc2,1
SPE_A93699261,Sodium Danshensu,sensitiv,94.76,85.56,67.7,-9.07,5.71,8.94,-1.51,-1.02,,other,Preclinical,Other,N,,,,,,,,,,,,,10512,PAFLSMZLRSPALU-UHFFFAOYSA-N,OC(Cc1ccc(O)c(O)c1)C(=O)O,1
SPE_K05919151,Dixanthogen,sensitiv,99.06,94.65,88.67,1.38,5.97,10.12,6.13,4.91,,other,Preclinical,Other,Y,,,,,,,,,,,,,10666,FVIGODVHAVLZOO-UHFFFAOYSA-N,CCOC(=S)SSC(=S)OCC,1
SPE_K63169195,U-0124,sensitiv,53.29,88.81,34.65,-9.69,6.17,12.33,-0.91,17.66,MEK inhibitor,other,Preclinical,Kinase,Y,,,,,,,,,,,,,11993,LBQNBMSPTURKGS-KQQUZDAGSA-N,CS\C(=C(/C#N)\C(=C(/N)\SC)\C#N)\N,1
SPE_K75649340,thioguanosine,sensitiv,100.08,79.58,41.48,12.03,6.31,9.91,16.05,110.58,purine antagonist,other,Phase 2,Enzyme,Y,,,,,,,,,,,,,12238,OTDJAMXESTUWLO-UUOKFMHZSA-N,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,1
SPE_K95573441,PFK-015,sensitiv,98.32,95.01,85.5,3.68,6.48,9.61,-20.02,101.32,phosphofructokinase inhibitor,PFKFB3,Phase 1,Kinase,Y,,,,,,,,,,,,,12663,UJJUKZPBUMCSJZ-BQYQJAHWSA-N,O=C(\C=C\c1ccc2ccccc2n1)c3ccncc3,1
SPE_K63712959,Temoporfin,sensitiv,82.44,77.84,5.8,-16.6,6.55,45.05,4.51,85.92,radical formation stimulant,other,Launched,Enzyme,N,,,,,,,,,,,,,6967,LYPFDBRUNKHDGX-UHFFFAOYSA-N,Oc1cccc(c1)c2c3CCc(n3)c(c4cccc(O)c4)c5ccc([nH]5)c(c6cccc(O)c6)c7ccc(n7)c(c8C=Cc2[nH]8)c9cccc(O)c9,1
SPE_A56892734,Esomeprazole magnesium trihydrate,sensitiv,94.74,99.74,96.87,-6.78,6.92,10.0,-3.33,26.41,proton pump inhibitor,"ATP4A, ATP4B",Launched,Channel,N,,,,,,,,,,,,,10283,KWORUUGOSLYAGD-UHFFFAOYSA-N,COc1ccc2c(c1)nc(S(=O)Cc3ncc(C)c(OC)c3C)n2[Mg]n4c(nc5cc(OC)ccc45)S(=O)Cc6ncc(C)c(OC)c6C,1
SPE_A49172652,LANSOPRAZOLE,sensitiv,97.15,98.57,96.07,-12.1,7.25,10.83,1.65,19.31,ATPase inhibitor,"ATP4A, ATP4B",Launched,Enzyme,N,,,,,,,,,,,,,348,MJIHNNLFOKEZEW-UHFFFAOYSA-N,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c2nc3ccccc3[nH]2,1
SPE_K28010364,PFK-158,sensitiv,52.44,79.2,47.53,14.83,7.65,10.42,0.32,1.89,phosphofructokinase inhibitor,PFKFB3,Phase 1,Kinase,Y,,,,,,,,,,,,,2491,IAJOMYABKVAZCN-AATRIKPKSA-N,FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1,1
SPE_K24548560,EVANS BLUE,EVANS BLUE,102.42,102.08,84.04,102.29,9.05,12.62,-16.19,34.84,glutamate receptor negative allosteric modulator,"GRIA1, PTPN1",Launched,GPCR,N,,,,,,,,,,,,,9591,COXVTLYNGOIATD-HVMBLDELSA-N,Cc1cc(ccc1\N=N\c2ccc3c(cc(c(N)c3c2O)S(=O)(=O)O)S(=O)(=O)O)c4ccc(\N=N\c5ccc6c(cc(c(N)c6c5O)S(=O)(=O)O)S(=O)(=O)O)c(C)c4,1
SPE_K56483981,chicago-sky-blue-6b,chicago-sky-blue-6b,100.9,94.51,30.7,100.29,9.82,73.05,-14.16,18.86,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,Preclinical,GPCR,N,,,,,,,,,,,,,11833,OHMJKMNGYYWCHB-HVMBLDELSA-N,COc1cc(ccc1\N=N\c2ccc3c(cc(c(N)c3c2O)S(=O)(=O)O)S(=O)(=O)O)c4ccc(\N=N\c5ccc6c(cc(c(N)c6c5O)S(=O)(=O)O)S(=O)(=O)O)c(OC)c4,1
SPE_K40654626,ditiocarb-sodium-trihydrate,sensitiv,96.58,89.89,60.3,-13.87,10.26,10.69,-0.14,12.55,,,,,Y,,,,,,,,,,,,,8471,LMBWSYZSUOEYSN-UHFFFAOYSA-N,CCN(CC)C(=S)S,1
SPE_A09094913,STRYCHNINE SULFATE,sensitiv,76.52,79.75,1.2,3.15,10.37,30.36,-14.11,29.04,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB",Preclinical,GPCR,N,,,,,,,,,,,,,9977,QMGVPVSNSZLJIA-OFYMUHMXSA-N,O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c7ccccc67,1
SPE_K26134695,calpeptin,calpeptin,72.3,57.5,-76.82,63.28,10.97,70.14,4.3,9.55,calpain inhibitor,other,Preclinical,Protease,Y,,,,,,,,,,,,,11127,PGGUOGKHUUUWAF-ROUUACIJSA-N,CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O,1
SPE_K82147103,lofepramine,sensitiv,81.74,68.1,-10.06,-24.06,11.42,34.27,-0.02,40.87,"norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI)","HTR1A, SLC6A2, SLC6A4",Launched,GPCR,N,,,,,,,,,,,,,8223,SAPNXPWPAUFAJU-UHFFFAOYSA-N,CN(CCCN1c2ccccc2CCc3ccccc13)CC(=O)c4ccc(Cl)cc4,1
SPE_K92980438,3-Bromopyruvic acid,sensitiv,78.92,74.01,21.38,-18.73,11.5,6184238.96,4.74,10.28,hexokinase inhibitor,HK2,Preclinical,Kinase,Y,,,,,,,,,,,,,12609,PRRZDZJYSJLDBS-UHFFFAOYSA-N,OC(=O)C(=O)CBr,1
SPE_K78126613,MENADIONE,MENADIONE,74.45,89.62,53.24,77.53,11.58,111.36,1.79,4.3,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1",Launched,DNA-RNA-Viral,Y,,,,,,,,,,,,,6035,MJVAVZPDRWSRRC-UHFFFAOYSA-N,CC1=CC(=O)c2ccccc2C1=O,1
SPE_A72297358,ozolinone,sensitiv,76.35,72.91,-6.13,3.46,11.64,35.3,13.43,2.47,diuretic,other,Phase 3,Other,Y,,,,,,,,,,,,,10385,NQFBZYYUAFJYNS-FPLPWBNLSA-N,CN1C(=O)C(S/C/1=C\C(=O)O)N2CCCCC2,1
SPE_K09126848,Nepicastat (hydrochloride),sensitiv,97.31,57.25,19.16,-15.2,12.26,8.24,-0.9,-2.48,dopamine beta hydroxylase inhibitor,DBH,Phase 2,Enzyme,Y,,,,,,,,,,,,,5723,YZZVIKDAOTXDEB-JTQLQIEISA-N,NCC1=CNC(=S)N1[C@H]2CCc3c(F)cc(F)cc3C2,1
SPE_K24715592,ETHACRIDINE LACTATE,ETHACRIDINE LACTATE,-168.35,-56.2,95.14,-84.3,12.35,0.9,0.2,4.01,DNA intercalating agent,other,Preclinical,DNA-RNA-Viral,N,,,,,,,,,,,,,9593,CIKWKGFPFXJVGW-UHFFFAOYSA-N,CCOc1ccc2nc3cc(N)ccc3c(N)c2c1,1
SPE_K35573744,erbstatin-analog,sensitiv,68.58,52.73,94.99,-54.61,13.0,2.96,-8.34,-26.12,"EGFR inhibitor, tyrosine kinase inhibitor",EGFR,Preclinical,Kinase,Y,,,,,,,,,,,,,11342,BQCNSTFWSKOWMA-GORDUTHDSA-N,COC(=O)\C=C\c1cc(O)ccc1O,1
SPE_K60230970,MG-132,MG-132,68.52,78.61,-29.72,81.07,13.15,0.0,-12.18,-11.44,proteasome inhibitor,PSMB1,Preclinical,Protease,Y,,,,,,,,,,,,,11911,TZYWCYJVHRLUCT-VABKMULXSA-N,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O,1
SPE_K76841105,Tazarotene (Avage),Tazarotene (Avage),-880.1,-692.49,108.07,-663.39,13.5,321.75,-2.4,0.9,retinoid receptor agonist,"RARA, RARB, RARG, RXRB",Launched,NHR,N,,,,,,,,,,,,,445,OGQICQVSFDPSEI-UHFFFAOYSA-N,CCOC(=O)c1ccc(nc1)C#Cc2ccc3SCCC(C)(C)c3c2,1
SPE_K36381762,nor-Binaltorphimine-dihydrochloride,sensitiv,93.17,60.39,33.24,-7.99,14.05,11.69,3.2,7.65,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",Preclinical,GPCR,N,,,,,,,,,,,,,11361,APSUXPSYBJVPPS-YAUKWVCOSA-N,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]56[C@@H](Oc1c25)c7[nH]c8[C@@H]9Oc%10c(O)ccc%11C[C@H]%12N(CC%13CC%13)CC[C@@]9(c%10%11)[C@@]%12(O)Cc8c7C[C@@]36O,1
SPE_K20605374,NSC697923,sensitiv,65.69,59.05,-40.51,5.82,14.6,11.05,-32.24,-0.42,ubiquitin-conjugating enzyme inhibitor,UBE2N,Preclinical,Enzyme,possibly,,,,,,,,,,,,,11006,GAUHIPWCDXOLCZ-UHFFFAOYSA-N,Cc1ccc(cc1)S(=O)(=O)c2oc(cc2)[N+](=O)[O-],1
SPE_K42205652,"MNS (3,4-Methylenedioxy-¦Â-nitrostyrene)",sensitiv,98.75,97.4,88.84,6.55,14.92,14.83,-3.06,-5.41,,,,,Y,,,,,,,,,,,,,11488,KFLWBZPSJQPRDD-UHFFFAOYSA-N,[O-][N+](=O)C=Cc1ccc2OCOc2c1,1
SPE_K20338176,CEFACLOR,sensitiv,75.98,74.44,23.21,-4.23,17.57,54.85,6.88,38.21,bacterial cell wall synthesis inhibitor,other,Launched,Antibacterial,Y,,,,,,,,,,,,,7998,QYIYFLOTGYLRGG-GPCCPHFNSA-N,N[C@@H](C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)Cl)c3ccccc3,1
SPE_K94485812,LDN-57444,LDN-57444,35.37,66.59,-70.21,54.14,17.85,0.62,3.58,-1.21,ubiquitin C-terminal hydrolase inhibitor,other,Preclinical,Enzyme,Y,,,,,,,,,,,,,12644,OPQRFPHLZZPCCH-LTGZKZEYSA-N,CC(=O)O\N=C/1\C(=O)N(Cc2cc(Cl)ccc2Cl)c3ccc(Cl)cc13,1
SPE_A19661776,MIANSERIN HYDROCHLORIDE,sensitiv,47.02,68.6,-40.18,-14.0,19.18,0.66,-2.44,-1.39,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7, OPRK1, SLC6A2, SLC6A3, SLC6A4",Launched,GPCR,N,,,,,,,,,,,,,8225,UEQUQVLFIPOEMF-UHFFFAOYSA-N,CN1CCN2C(C1)c3ccccc3Cc4ccccc24,1
SPE_K05445342,WP1066,sensitiv,97.69,92.28,63.85,14.51,21.17,12.61,-24.41,8.19,STAT inhibitor,STAT3,Phase 1,Enzyme,Y,,,,,,,,,,,,,4271,VFUAJMPDXIRPKO-LQELWAHVSA-N,C[C@H](NC(=O)\C(=C\c1cccc(Br)n1)\C#N)c2ccccc2,0
SPE_K38287497,Narlaprevir,Narlaprevir,76.12,55.34,-66.14,58.94,24.35,2.02,2.79,7.98,HCV inhibitor,other,Phase 2/Phase 3,Protease,N,,,,,,,,,,,,,3564,RICZEKWVNZFTNZ-LFGITCQGSA-N,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC3(CS(=O)(=O)C(C)(C)C)CCCCC3)C(C)(C)C)C2(C)C)C(=O)C(=O)NC4CC4,0
SPE_K58299615,Ro-90-7501,sensitiv,-435.69,-372.81,-78.87,-453.25,25.55,0.0,-5.05,2.32,,APP,Preclinical,Other,N,,,,,,,,,,,,,11864,PAGZCEHLFCJSPV-UHFFFAOYSA-N,Nc1ccc(cc1)c2nc3ccc(cc3[nH]2)c4nc5ccc(N)cc5[nH]4,0
SPE_A56241705,trimethoquinol,sensitiv,73.89,55.42,24.02,-5.56,28.24,13.31,7.34,-3.22,adrenergic receptor antagonist,"ADRB2, ADRB3",Launched,GPCR,N,,,,,,,,,,,,,4021,RGVPOXRFEPSFGH-UHFFFAOYSA-N,COc1cc(CC2NCCc3cc(O)c(O)cc23)cc(OC)c1OC,0
SPE_A49035384,METHACYCLINE HYDROCHLORIDE,sensitiv,95.23,91.04,72.42,10.26,31.01,42.59,-2.41,9.09,protein synthesis inhibitor,other,Launched,DNA-RNA-Viral,Y,,,,,,,,,,,,,10231,QNJKSUYWBCNWFI-KCDYASHQSA-N,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(=O)N)C1=O,0
SPE_K89464729,GSK269962,sensitiv,29.11,60.35,-11.15,-11.91,42.25,39.77,-13.92,-4.36,,,,,N,,,,,,,,,,,,,12541,YOVNFNXUCOWYSG-UHFFFAOYSA-N,CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)c6nonc6N,0
SPE_K43644456,Degrasyn (WP1130),sensitiv,55.56,59.37,-36.27,-6.59,46.02,105.3,-39.94,-11.53,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",Preclinical,Enzyme,Y,,,,,,,,,,,,,11520,LIDOPKHSVQTSJY-VMEIHUARSA-N,CCC[C@H](NC(=O)\C(=C\c1cccc(Br)n1)\C#N)c2ccccc2,0
SPE_K28354016,HOMIDIUM BROMIDE,sensitiv,42.06,60.19,-46.71,30.02,54.5,34.61,12.44,0.42,,other,Preclinical,Other,Y,,,,,,,,,,,,,11188,HZXSCJPGYKAURD-UHFFFAOYSA-N,CC[N]1=C(c2ccccc2)c3cc(N)ccc3c4ccc(N)cc14,0
SPE_K14821965,propidium-iodide,sensitiv,82.9,90.94,79.71,55.99,56.93,21.11,3.63,69.67,,ACHE,Preclinical,Other,Y,,,,,,,,,,,,,10877,YCIBQMXLJSWKKE-UHFFFAOYSA-N,CC[N](C)(CC)CCC[N]1=C(c2ccccc2)c3cc(N)ccc3c4ccc(N)cc14,0
SPE_A92800748,Tie2 kinase inhibitor,Tie2 kinase inhibitor,-572.83,-462.47,-201.98,-447.94,80.0,14.97,-9.47,-4.11,TIE tyrosine kinase inhibitor,"KDR, MAPK14",Preclinical,Kinase,N,,,,,,,,,,,,,10502,SINQIEAULQKUPD-UHFFFAOYSA-N,COc1ccc2cc(ccc2c1)c3nc([nH]c3c4ccncc4)c5ccc(cc5)S(=O)C,0
SPE_K21152241,enoximone,sensitiv,84.35,68.44,-28.07,-0.53,158.45,57.42,5.84,6.41,phosphodiesterase inhibitor,PDE3A,Launched,,N,,,,,,,,,,,,,8754,ZJKNESGOIKRXQY-UHFFFAOYSA-N,CSc1ccc(cc1)C(=O)c2nc(O)[nH]c2C,0
SPE_K32456483,PRT4165,PRT4165,81.04,75.65,11.06,60.38,208.06,0.0,30.53,3.39,polycomb repressive complex inhibitor,PRC1,Preclinical,Enzyme,Y,,,,,,,,,,,,,11272,OMHZFEWYVFWVLI-UHFFFAOYSA-N,O=C1C(=Cc2cccnc2)C(=O)c3ccccc13,0
SPE_K94342292,NS-11021,sensitiv,51.73,55.42,-9.91,-13.58,255.07,0.0,25.42,19.33,,,,,N,,,,,,,,,,,,,12640,MDKAFDIKYQMOMF-UHFFFAOYSA-N,FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2c3nnn[nH]3)cc(c1)C(F)(F)F,0
SPE_K86063171,EN460,sensitiv,80.59,93.45,71.76,35.44,261.11,24.7,3.56,1.81,endoplasmic reticulum oxidation inhibitor,ERO1A,Preclinical,Enzyme,Y,,,,,,,,,,,,,12472,RSLFQCNAOMQAIH-WJDWOHSUSA-N,OC(=O)c1cc(ccc1Cl)N2N=C(\C(=C\c3oc(cc3)c4ccccc4)\C2=O)C(F)(F)F,0
SPE_A22380646,Pantoprazole (sodium),sensitiv,99.86,75.99,-3.44,-9.16,330.8,0.0,9.29,2.84,,,,,N,,,,,,,,,,,,,7040,IQPSEEYGBUAQFF-UHFFFAOYSA-N,COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,0
SPE_K69280563,Vinorelbine (ditartrate),sensitiv,94.36,97.77,94.83,-17.58,346.31,23.91,-16.74,-6.6,,,,,N,,,,,,,,,,,,,14460,GBABOYUKABKIAF-DTFZPXFVSA-N,CCC1=CC2CN(C1)Cc3c([nH]c4ccccc34)[C@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](OC(=O)C)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)OC,0
SPE_K79353516,CY208-243,sensitiv,52.66,61.02,-23.89,-3.59,765.47,0.0,8.25,-8.0,dopamine receptor agonist,CALY,Phase 2,GPCR,N,,,,,,,,,,,,,7897,WRNKIDLXXXIELU-IEBWSBKVSA-N,CN1Cc2ccccc2[C@H]3[C@H]1Cc4c[nH]c5cccc3c45,0
SPE_K33623053,Rose Bengal Sodium Salt,Rose Bengal Sodium Salt,99.6,74.85,-2.27,69.98,1176.55,26.97,22.43,15.27,immunostimulant,,Phase 2,,N,,,,,,,,,,,,,5272,IICCLYANAQEHCI-UHFFFAOYSA-N,Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C24OC(=O)c5c(Cl)c(Cl)c(Cl)c(Cl)c45)c1I,0
SPE_A78111609,TNP-470,TNP-470,65.34,58.16,-27.04,55.17,1242.46,0.01,-6.01,13.28,cell cycle inhibitor,METAP2,Phase 2,Enzyme,Y,,,,,,,,,,,,,10420,MSHZHSPISPJWHW-MIQCOGSQSA-N,CO[C@@H]1[C@@H](CC[C@]2(CO2)C1[C@@]3(C)O[C@@H]3CC=C(C)C)OC(=O)NC(=O)CCl,0
SPE_K61443506,NEXIUM (esomeprazole magnesium),sensitiv,99.05,99.08,94.93,-9.0,1700.15,41.23,0.55,1.24,ATPase inhibitor,ATP4A,Launched,Enzyme,N,,,,,,,,,,,,,688,SUBDBMMJDZJVOS-DEOSSOPVSA-N,COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc3ncc(C)c(OC)c3C,0
SPE_K28861668,A 922500,A 922500,-344.1,-224.51,-43.78,-194.63,1901.49,988.5,1.77,-2.3,diacylglycerol O acyltransferase inhibitor,DGAT1,Preclinical,Enzyme,N,,,,,,,,,,,,,11201,BOZRFEQDOFSZBV-PKTZIBPZSA-N,OC(=O)[C@H]1CCC[C@H]1C(=O)c2ccc(cc2)c3ccc(NC(=O)Nc4ccccc4)cc3,0
SPE_K21017401,CEFTIOFUR HYDROCHLORIDE,sensitiv,83.77,73.14,-9.3,-4.24,2645.25,27.01,2.29,5.34,bacterial cell wall synthesis inhibitor,,,,Y,,,,,,,,,,,,,11016,ZBHXIWJRIFEVQY-IHMPYVIRSA-N,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)CSC(=O)c3occc3)\c4csc(N)n4,0
SPE_K97534525,NITROXOLINE,sensitiv,27.35,55.25,-61.53,-8.17,3726.71,0.67,6.25,3.81,cathepsin inhibitor,METAP2,Launched,Protease,N,,,,,,,,,,,,,3129,RJIWZDNTCBHXAL-UHFFFAOYSA-N,Oc1ccc(c2cccnc12)[N+](=O)[O-],0
SPE_K18347943,ER-50891,sensitiv,-198.67,-199.66,-305.75,-301.17,3821.48,14.12,23.4,42.24,,,,,N,,,,,,,,,,,,,10957,LSGNKLDHMQVTEK-UHFFFAOYSA-N,CC(C)c1cccc2c(cc(nc12)c3ccc([nH]3)c4ccc(cc4)C(=O)O)c5ccccc5,0
SPE_K34581968,BMS-536924,sensitiv,-306.74,-351.0,-183.47,-381.53,4648.33,31573.36,-6.91,4.17,IGF-1 inhibitor,,,,N,,,,,,,,,,,,,11326,ZWVZORIKUNOTCS-OAQYLSRUSA-N,Cc1cc(cc2nc([nH]c12)C3=C(NC[C@@H](O)c4cccc(Cl)c4)C=CNC3=O)N5CCOCC5,0
SPE_A64227845,SKF-77434,sensitiv,80.98,59.09,27.85,3.95,5113.13,14.41,-1.85,-5.32,dopamine receptor agonist,DRD1,Preclinical,GPCR,N,,,,,,,,,,,,,10330,QBUVZVXIRYFENV-UHFFFAOYSA-N,Oc1cc2CCN(CC=C)CC(c3ccccc3)c2cc1O,0
SPE_K70344361,NH125,sensitiv,83.4,77.79,25.73,36.29,5142.25,0.85,-34.09,37.73,eukaryotic translation elongation factor 2 inhibitor,,Preclinical,,Y,,,,,,,,,,,,,12121,SCZGZIJDYBVGRS-UHFFFAOYSA-N,CCCCCCCCCCCCCCCC[N]1=C(C)N(Cc2ccccc2)C=C1,0
SPE_K17026858,Hoechst 33258,Hoechst 33258,-506.92,-463.31,-157.5,-471.16,8117.11,40444.16,-9.91,1.1,DNA inhibitor,other,Phase 2,DNA-RNA-Viral,N,,,,,,,,,,,,,9384,INAAIJLSXJJHOZ-UHFFFAOYSA-N,CN1CCN(CC1)c2ccc3nc([nH]c3c2)c4ccc5nc([nH]c5c4)c6ccc(O)cc6,0
SPE_K00152668,Adarotene,Adarotene,-322.61,-387.09,-157.26,-348.55,8725.9,12.64,-14.34,13.87,retinoid receptor agonist,"RARB, RARG",Phase 1,NHR,N,,,,,,,,,,,,,4419,QAWBIEIZDDIEMW-FPYGCLRLSA-N,OC(=O)\C=C\c1ccc(cc1)c2ccc(O)c(c2)C34CC5CC(CC(C5)C3)C4,0
SPE_A09828896,SKF-81297,sensitiv,94.45,64.62,67.01,-13.25,10559.28,6.28,1.02,-4.21,dopamine receptor agonist,"DRD1, DRD5",Preclinical,GPCR,N,,,,,,,,,,,,,9982,GHWJEDJMOVUXEC-UHFFFAOYSA-N,Oc1cc2C(CNCCc2c(Cl)c1O)c3ccccc3,0
SPE_K10549975,Vinflunine Ditartrate,sensitiv,91.96,97.15,82.41,-14.38,12170.07,37.39,0.59,-7.06,microtubule inhibitor,,Launched,,N,,,,,,,,,,,,,10767,NOSAJPUYIASWEH-USRBKURZSA-N,CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c5cc(OC)c(cc45)[C@]6(C[C@@H]7C[C@H](C[N@](CCc8c6[nH]c9ccccc89)C7)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(=O)C)C(=O)OC,0
SPE_K62949423,NSC-625987,sensitiv,78.66,95.24,84.24,-11.42,22814.82,11.76,-2.58,-7.36,CDK inhibitor,"CDK2, CDK4",Preclinical,Kinase,Y,,,,,,,,,,,,,11988,KFAKESMKRPNZTM-UHFFFAOYSA-N,COc1ccc(OC)c2C(=S)c3ccccc3Nc12,0
SPE_K15426076,Iguratimod,Iguratimod,-421.6,-348.85,-38.91,-326.98,30178.41,1.19,-0.93,34.21,"cyclooxygenase inhibitor, NFkB pathway inhibitor",PTGS2,Launched,Enzyme,Y,,,,,,,,,,,,,458,ANMATWQYLIFGOK-UHFFFAOYSA-N,CS(=O)(=O)Nc1cc2OC=C(NC=O)C(=O)c2cc1Oc3ccccc3,0
SPE_K96354014,NIFEDIPINE,sensitiv,89.46,75.51,26.53,-12.47,65539.5,0.08,-3.15,-1.74,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNB2, CALM1, GLRA1, GLRA3, GLRB, KCNA1, KCNA5, NR1I2, TRPM3",Launched,Channel,N,,,,,,,,,,,,,402,HYIMSNHJOBLJNT-UHFFFAOYSA-N,COC(=O)C1=C(C)NC(=C(C1c2ccccc2[N+](=O)[O-])C(=O)OC)C,0
SPE_A55962179,OMEPRAZOLE,sensitiv,97.49,98.48,97.96,-5.53,98199.07,21.78,1.34,6.84,ATPase inhibitor,"ATP4A, CLCN2",Launched,Enzyme,N,,,,,,,,,,,,,118,SUBDBMMJDZJVOS-UHFFFAOYSA-N,COc1ccc2nc([nH]c2c1)S(=O)Cc3ncc(C)c(OC)c3C,0
SPE_K72922393,linsidomine,sensitiv,73.86,60.42,-39.83,-14.9,98675.65,0.0,0.84,-6.94,nitric oxide donor,,Launched,,Y,,,,,,,,,,,,,5489,HLJBZZLOFWUPLI-UHFFFAOYSA-N,NC1=C[N](=NO1)N2CCOCC2,0
SPE_K72226571,A77636,sensitiv,97.28,96.15,84.68,-13.97,242733.04,12.14,0.39,-7.16,dopamine receptor agonist,CALY,Preclinical,GPCR,N,,,,,,,,,,,,,12161,QLJOSZATCBCBDR-DFKUFRTHSA-N,NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)C34CC5CC(CC(C5)C3)C4,0
DOM_SIM_505,Felbinac ethyl,,,,,,0.2,0.27,,,,,,,,DOM_0000002_L01,J019,K,12.0,inhibitor,101.83,99.77,92.69,96.2,-0.19,-5.74,N,7318,NPPJLSILDPVHCM-UHFFFAOYSA-N,CCOC(=O)Cc1ccc(cc1)c2ccccc2,1
DOM_SIM_068,Amlexanox ,,,,,,1.01,3.65,,,,,,,,DOM_0000001_L01,M019,D,1.0,autofl_inhibitor,112.9,-1115.38,96.1,-716.86,-0.05,-3.56,N,8718,SGRYPYWGNKJSDL-UHFFFAOYSA-N,CC(C)c1ccc2Oc3nc(N)c(cc3C(=O)c2c1)C(=O)O,1
DOM_SIM_032,Levofloxacin ,,,,,,1.7,4.42,,,,,,,,DOM_0000001_L01,G007,A,1.0,autofl_inhibitor,106.0,-1115.94,93.65,-710.24,0.12,-2.11,N,408,GSDSWSVVBLHKDQ-JTQLQIEISA-N,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(=O)O,1
DOM_SIM_379,KW 2449,,,,,,2.7,7.18,,,,,,,,DOM_0000002_L01,O015,C,12.0,autofl_inhibitor,108.04,-1106.0,99.69,-757.4,0.25,-5.59,N,9052,YYLKKYCXAOBSRM-JXMROGBWSA-N,O=C(N1CCNCC1)c2ccc(\C=C\c3n[nH]c4ccccc34)cc2,1
DOM_SIM_488,Razoxane,,,,,,3.19,5.21,,,,,,,,DOM_0000002_L01,H005,I,12.0,inhibitor,102.45,100.06,101.07,100.66,-0.21,0.06,Y,5207,BMKDZUISNHGIBY-UHFFFAOYSA-N,CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,1
DOM_SIM_528,6-aminochrysene,,,,,,3.39,10.28,,,,,,,,DOM_0000002_L01,P005,L,12.0,activator,-65.23,-248.82,-117.61,-230.82,1.49,-2.04,N,7427,KIVUHCNVDWYUNP-UHFFFAOYSA-N,Nc1cc2c3ccccc3ccc2c4ccccc14,1
DOM_SIM_486,Dexrazoxane hydrochloride ,,,,,,6.24,10.0,,,,,,,,DOM_0000002_L01,H001,H,12.0,inhibitor,100.57,98.63,30.8,88.99,0.12,9.53,Y,6475,BMKDZUISNHGIBY-ZETCQYMHSA-N,C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,1
DOM_SIM_440,Tasuldine ,,,,,,9.03,11.18,,,,,,,,DOM_0000002_L01,M006,G,12.0,inhibitor,97.58,98.14,68.98,94.07,-0.15,-3.99,Y,8103,HMCTXMOKMWELFJ-UHFFFAOYSA-N,C(Sc1ncccn1)c2cccnc2,1
DOM_SIM_596,Daclatasvir dihydrochloride ,,,,,,9.25,10.0,,,,,,,,DOM_0000002_L01,D006,O,12.0,autofl_inhibitor,3.6,-1033.87,100.4,-755.0,5.77,-8.81,N,1094,FKRSSPOQAMALKA-CUPIEXAXSA-N,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c2ncc([nH]2)c3ccc(cc3)c4ccc(cc4)c5cnc([nH]5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C,1
DOM_SIM_537,Parthenolide,,,,,,10.04,20.0,,,,,,,,DOM_0000002_L01,B004,M,12.0,inhibitor,77.16,86.19,-12.23,56.54,-0.34,-43.19,Y,7651,KTEXNACQROZXEV-SLXBATTESA-N,C\C\1=C/CC[C@@]2(C)O[C@H]2[C@H]3OC(=O)C(=C)[C@@H]3CC1,1
DOM_SIM_299,(-)-Epicatechin,,,,,,16.9,30.48,,,,,,,,DOM_0000001_L01,N020,P,1.0,inhibitor,101.03,99.75,83.11,86.9,-0.12,2.17,Y,7747,PFTAWBLQPZVEMU-UKRRQHHQSA-N,O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c3ccc(O)c(O)c3,1
DOM_SIM_084,Linifanib ,,,,,,20.0,20.0,,,,,,,,DOM_0000001_L01,A012,G,1.0,activator,-132.3,-666.12,-203.76,-455.46,4.22,-9.07,N,3998,MPVGZUGXCQEXTM-UHFFFAOYSA-N,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)c3cccc4[nH]nc(N)c34)c1,0
DOM_SIM_055,Luminol sodium salt,,,,,,20.0,20.0,,,,,,,,DOM_0000001_L01,K013,C,1.0,autofl_inhibitor,172.23,-481.89,156.93,-310.81,-0.06,0.7,Y,5316,HWYHZTIRURJOHG-UHFFFAOYSA-N,Nc1cccc2C(=O)NNC(=O)c12,0
DOM_SIM_070,Adrenaline,,,,,,20.0,20.0,,,,,,,,DOM_0000001_L01,O003,E,1.0,inhibitor,66.61,73.95,-34.41,46.59,0.07,10.75,N,703,UCTWMZQNUQWSLP-VIFPVBQESA-N,CNC[C@H](O)c1ccc(O)c(O)c1,0
DOM_SIM_124,Baricitinib ,,,,,,20.0,20.0,,,,,,,,DOM_0000001_L01,I016,H,1.0,autofl_inhibitor,97.87,-1111.46,100.03,-707.34,-0.26,2.24,Y,1102,XUZMWHLSFXCVMG-UHFFFAOYSA-N,CCS(=O)(=O)N1CC(CC#N)(C1)n2cc(cn2)c3ncnc4[nH]ccc34,0
DOM_SIM_133,Tretinoin ,,,,,,20.0,20.0,,,,,,,,DOM_0000001_L01,K014,I,1.0,inhibitor,47.27,71.73,-64.74,41.62,-0.05,1.01,Y,511,SHGAZHPCJJPHSC-YCNIQYBTSA-N,C\C(=C/C=C/C(=C/C(=O)O)/C)\C=C\C1=C(C)CCCC1(C)C,0
DOM_SIM_151,Clevidipine ,,,,,,20.0,20.0,,,,,,,,DOM_0000001_L01,O012,J,1.0,autofl_inhibitor,48.84,-209.3,64.15,-140.89,0.27,-0.29,N,604,KPBZROQVTHLCDU-UHFFFAOYSA-N,CCCC(=O)OCOC(=O)C1=C(C)NC(=C(C1c2cccc(Cl)c2Cl)C(=O)OC)C,0
DOM_SIM_204,Metazosin,,,,,,20.0,20.0,,,,,,,,DOM_0000001_L01,L003,L,1.0,autofl_inhibitor,1.64,-1013.17,91.75,-711.98,0.1,-0.46,N,8081,YEOTYALSMRNXLJ-UHFFFAOYSA-N,COC(C)C(=O)N1CCN(CC1)c2nc(N)c3cc(OC)c(OC)cc3n2,0
DOM_SIM_280,Noradrenaline,,,,,,20.0,20.0,,,,,,,,DOM_0000001_L01,L002,N,1.0,inhibitor,65.75,75.16,-31.86,54.04,-0.04,-1.57,N,8837,SFLSHLFXELFNJZ-QMMMGPOBSA-N,NC[C@H](O)c1ccc(O)c(O)c1,0
DOM_SIM_345,Ruxolitinib phosphate ,,,,,,20.0,20.0,,,,,,,,DOM_0000002_L01,G019,A,12.0,autofl_inhibitor,102.59,-1113.53,78.76,-748.53,0.1,-8.58,Y,1076,HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34,0
DOM_SIM_432,Danofloxacin ,,,,,,20.0,9.99,,,,,,,,DOM_0000002_L01,K008,E,12.0,autofl_inhibitor,70.31,-725.74,147.02,-588.05,0.02,1.21,N,7017,QMLVECGLEOSESV-VXGBXAGGSA-N,CN1C[C@H]2C[C@@H]1CN2c3cc4N(C=C(C(=O)O)C(=O)c4cc3F)C5CC5,0
DOM_SIM_434,Fenoldopam mesilate ,,,,,,20.0,20.0,,,,,,,,DOM_0000002_L01,K014,F,12.0,inhibitor,101.9,99.05,89.28,85.76,-0.06,-7.64,N,98,TVURRHSHRRELCG-UHFFFAOYSA-N,Oc1ccc(cc1)C2CNCCc3c(Cl)c(O)c(O)cc23,0
DOM_SIM_578,Grazoprevir hydrate ,,,,,,20.0,10.16,,,,,,,,DOM_0000002_L01,M017,N,12.0,activator,-62.55,-231.59,-61.53,-178.08,-0.09,-8.21,Y,3038,OBMNJSNZOWALQB-NCQNOWPTSA-N,COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N5C[C@@H](C[C@H]5C(=O)N[C@@]6(C[C@H]6C=C)C(=O)NS(=O)(=O)C7CC7)Oc3nc2c1)C(C)(C)C,0
